Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Oct 1;4(10):e2131749.
doi: 10.1001/jamanetworkopen.2021.31749.

Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis

Jia-Jin Chen  1 , Tao Han Lee  1 , Ya-Chung Tian  1   2 , Cheng-Chia Lee  1   2 , Pei-Chun Fan  1   2 , Chih-Hsiang Chang  1   2
Affiliations
Meta-Analysis

Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis

Jia-Jin Chen et al. JAMA Netw Open. .

Abstract

Importance: Adults receiving dialysis treatment have a higher likelihood of death when infected with SARS-CoV-2 than adults not receiving dialysis treatment. To date, the immune response of people receiving dialysis after SARS-CoV-2 vaccination has not been systematically discussed.

Objective: To assess immunogenicity rates in people with end-stage kidney disease (ESKD) receiving SARS-CoV-2 vaccines, explore postvaccination potential risk factors for nonresponse, and assess whether receiving dialysis is associated with different antibody response rates compared with the nondialysis population.

Data sources: This systematic review and meta-analysis used articles from PubMed, Medline, and Embase published before July 30, 2021, as well as articles in the medRxiv preprint server.

Study selection: Studies that evaluated the immunogenicity rate according to the postvaccine antibody response rate in patients with ESKD receiving dialysis were selected.

Data extraction and synthesis: The meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. A random-effects model was used. Two independent reviewers conducted the literature search and extracted the data.

Main outcomes and measures: The primary outcome was the pooled antibody postvaccine response rates in individuals with ESKD. The secondary outcomes were pooled response rates in individuals receiving and not receiving dialysis. Subgroup analysis and meta-regression were conducted to identify the sources of heterogeneity.

Results: A total of 32 studies were included. The overall immunogenicity rate of the dialysis group was 86% (95% CI, 81%-89%). Meta-regression showed a significant difference was detected in the postvaccine response rate on the basis of prevalence of diabetes (regression coefficient, -0.06; 95% CI, -0.10 to -0.02; P = .004). Compared with nondialysis controls, patients in the dialysis group had a lower response rate after the first (relative risk [RR], 0.61; 95% CI, 0.47-0.79; I2 = 70.2%) and second (RR, 0.88; 95% CI, 0.82-0.93; I2 = 72.2%) doses, with statistically significantly increased RR between first and second doses (P = .007).

Conclusions and relevance: These findings suggest that the immunogenicity rate among patients receiving dialysis was 41% after the first dose and 89% after the second dose. Diabetes might be a risk factor for nonresponse in the dialysis population. Patients receiving dialysis had a poorer antibody response rate than did individuals not receiving dialysis, particularly after the first dose.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Forest Plots of Immunogenicity Rates
Figure 2.
Figure 2.. Forest Plots of Immunogenicity Rates By Vaccine Protocol Status
Figure 3.
Figure 3.. Association of Diabetes Prevalence and Immunogenicity Rates in the SARS-CoV-2–Naive Dialysis Population With Complete Vaccine Protocol
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ng JH, Hirsch JS, Wanchoo R, et al. ; Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium . Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020;98(6):1530-1539. doi:10.1016/j.kint.2020.07.030 - DOI - PMC - PubMed
    1. Jung HY, Lim JH, Kang SH, et al. . Outcomes of COVID-19 among patients on in-center hemodialysis: an experience from the epicenter in South Korea. J Clin Med. 2020;9(6):E1688. doi:10.3390/jcm9061688 - DOI - PMC - PubMed
    1. Chewcharat A, Chang YT, Sise ME, Bhattacharyya RP, Murray MB, Nigwekar SU. Phase-3 randomized controlled trials on exclusion of participants with kidney disease in COVID-19. Kidney Int Rep. 2021;6(1):196-199. doi:10.1016/j.ekir.2020.10.010 - DOI - PMC - PubMed
    1. Ikizler TA, Coates PT, Rovin BH, Ronco P. Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. Kidney Int. 2021;99(6):1275-1279. doi:10.1016/j.kint.2021.04.007 - DOI - PMC - PubMed
    1. Yi SG, Knight RJ, Graviss EA, et al. . Kidney transplant recipients rarely show an early antibody response following the first COVID-19 vaccine administration. Transplantation. 2021;105(7):e72-e73. doi:10.1097/TP.0000000000003764 - DOI - PubMed

Publication types

MeSH terms

Substances